Senior Scientific Director Pete Knox reports on current and emerging GIST treatments and the mutations they address. New research in GIST is happening, and there may be even more therapies around the corner.
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Richard Schoenbohm shares his story.
CTOS, "The Connective Tissue Oncology Society", is an organization of medical specialists and researchers who specialize in bone and soft tissue tumors. They hold a meeting every year to discuss the latest innovations in this area. This year the meeting took place in Tokyo from November 13 until 16.
International advocates meet in Wayne, NJ, at the annual New Horizons GIST Conference to discuss scientific updates, regional issues, and unmet needs for the global GIST community in May 2019.
The INTRIGUE study is a Phase 3 clinical trial testing the investigational drug ripretinib (DCC-2618) for patients living with GIST that are no longer on imatinib due to progression or intolerance.
At 39-years-old, Fatema Suterwala was preparing to say goodbye to her husband and young son. Confused by this cruel twist of fate and wracked with pain, she was saved by a collaboration of medical [...]
Newly Diagnosed | Glossary | GIST Education | GIST FAQs | Pathology Report Page updated 11/2/2022 What happens once you’ve been diagnosed with GIST Once you’re been diagnosed, your medical [...]
Michael C. Heinrich, MD Knight Cancer Institute Sameer Rastogi, MD All India Institute of Medical Sciences Peter Reichardt, MD Helios Klinikum Berlin-Buch Gary [...]
If you didn't find what you were looking for, try a new search!
